Dorothee Buttigieg

Dorothee Buttigieg currently serves as the Head of the Neuropharmacology Department at NeuronExperts, a leading private company specializing in neurodrug discovery and neurodegenerative disease research. In this strategic leadership role, she oversees the development and optimization of innovative cell-based assays that model complex neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis (ALS). Her expertise in both applied and fundamental neuroscience research enables her to guide multidisciplinary teams in designing robust in vitro and in vivo models, leveraging advanced techniques like high-content screening, cytometry en flux, and molecular biology to identify promising therapeutic candidates.

Dorothee’s work at NeuronExperts involves not only the scientific development of disease models but also the strategic planning of research axes aligned with industry needs. She manages a diverse client prospect database, collaborating closely with biotech and big pharma partners to design and execute studies that meet rigorous validation standards. Her role encompasses project management, ensuring that studies are conducted with scientific rigor, regulatory compliance, and clear deliverables. Her deep knowledge of drug discovery processes, coupled with her skills in cell culture, molecular biology, and in vitro/in vivo assays, positions her as a key driver in advancing neurotherapeutic innovations.

With a double competence as an engineer in biotechnology and a PhD in neuroscience, Dorothee combines technical excellence with strategic vision, fostering collaborations that accelerate the translation of scientific insights into viable treatments for neurodegenerative diseases. Her leadership continues to shape the future of neuropharmacology research at NeuronExperts, making her a pivotal figure in the field.